Bausch + Lomb Announces Statistically Significant Topline Re

Bausch + Lomb Announces Statistically Significant Topline Results from the Second Phase 3 Trial Of NOV03 (perfluorohexyloctane) in Dry Eye Disease Associated with Meibomian Gland Dysfunction

Bausch + Lomb Announces Statistically Significant Topline Results from the Second Phase 3 Trial Of NOV03 (perfluorohexyloctane) in Dry Eye Disease Associated with Meibomian Gland Dysfunction

prnewswire.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from prnewswire.com Daily Mail and Mail on Sunday newspapers.

Related Keywords

Germany , Heidelberg , Baden Wüberg , Cambridge , Cambridgeshire , United Kingdom , United States , Canada , Americans , Canadian , Lainie Keller , Novaliq Gmb , Aust Prescr , Simone Angstmann Mehr , Arthur Shannon , Bausch Health Companies Inc , Linkedin , Twitter , Bausch Health Investor Contact , Exchange Commission , Gmbh Co , National Eye Institute , Bausch Health Media Contact , Bausch Lomb Incorporated , Health Sciences , Bausch Health , Novaliq Inc , Corneal Fluorescein Staining , Hopp Biotech , Health Companies , Canadian Securities Administrators , Dry Eye , Ocul Immunol , Novaliq Gmbh , Randomized Clinical Study , Assess Efficacy , Publish Ahead , Lomb Incorporated , Media Contact , Health Investor Contact , Health Media Contact ,